On September 10, 2020 CMAB Biopharma (Suzhou) Inc. ("CMAB"), and Laekna Therapeutics Shanghai Co., Ltd. ("Laekna Therapeutics"), reported a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization (Press release, CMAB Biopharma, SEP 10, 2020, View Source [SID1234564977]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Signing Ceremony of Strategic Colaboration Between laekna Therapeutics and CMAB Biopharma
According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005). Services to be provided by CMAB include technology transfer, process development, GMP clinical drug substance and drug product manufacturing to support IND filing in China and in the US. These services will facilitate the global development and future commercialization of LAE005.

Laekna Therapeutics is a biotechnology innovation company focusing on the research and development of new generation of small molecules for target therapy and antibodies in the field of oncology and liver diseases. In February 2020, Laekna Therapeutics obtained the exclusive global development and commercialization rights for LAE005 from the Novartis group, Switzerland. At present, LAE005 has completed phase I clinical trials which confirmed the tolerability, safety and preliminary anti-cancer efficacy in different solid tumors, including triple negative breast cancer.

Laekna Therapeutics is applying for the permission of clinical trials for LAE005 both in China and in the US. "We are looking forward to the results of clinical efficacy and safety of LAE005. In the recent years, cancer therapy has entered a brand new era of immuno-oncology. The combination of anti-PD-L1 antibody and AKT inhibitor, such as LAE005 plus Afuresertib, is one of the most innovative therapies among many different combination therapies. Afuresertib is an AKT inhibitor of Laekna Therapeutics that is currently undergoing phase II global clinical trials in both China and the United States, which has great potential for the treatment of different cancers. Laekna Therapeutics is committed to bringing more safe, precise and personalized treatments to cancer patients globally, especially in China," said Dr. Chris Lu, founder and CEO of Laekna Therapeutics, "We are pleased to work closely with CMAB to provide process development and production of clinical trial drugs for anti-PD-L1 candidate. The excellent technology, experience and service of CMAB assure us that they can support Laekna’s clinical and commercial needs for our innovative pipeline and that our joint efforts will surely accelerate the benefits to cancer patients worldwide."

Located in Suzhou Biotech Industrial Park (BioBAY), CMAB is currently the fastest growing pure-play biopharmaceutical CDMO company in China. It is committed to using disruptive technologies to meet its customer’s needs as quickly as possible. Dr. Yongzhong Wang, CEO of CMAB, said: "Since our establishment in 2017, CMAB has successfully helped many partners gain valuable milestones in the new drug development and has also successfully completed the production of cGMP batches for several different clinical candidates being developed by leading biopharmaceutical enterprises. Since 2019, CMAB has continuously hired high-quality talent at home and abroad. At present, CMAB has nearly 260 employees, forming a stable and experienced team. As a respectable enterprise in the industry, Laekna Therapeutics has built up an experienced Sino-US operational team in a few years, and successfully and efficiently introduced a number of clinically validated new product candidates. We are very happy to establish a strategic cooperation with Laekna Therapeutics. The CMAB team will make every effort to realize the global development and commercialization of LAE005, the first biopharmaceutical project of Laekna Therapeutics."

On September 10, 2020 DURECT Corporation (Nasdaq: DRRX) reported that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Press release, DURECT, SEP 10, 2020, https://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-september-virtual-investor-conferences-301127214.html [SID1234564976]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HC Wainwright 22nd Annual Global Investment Conference
Date Monday, September 14
Time: 2:30-2:50 PM EDT (Fireside Chat with Ed Arce)
Webcast: View Source

Cantor Fitzgerald Virtual Global Healthcare Conference
Date Tuesday, September 15
Time 10-10:30am EDT (Fireside Chat with Ellie Merle)
Webcast: View Source

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 22
Time: 11:40am-12:20pm EDT (Fireside chat with Francois Brisebois)
Webcast: View Source

On September 10, 2020 Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, reported that its leadership team will be presenting an update on Appili’s programs at two upcoming investor conferences (Press release, Appili Therapeutics, SEP 10, 2020, View Source [SID1234564975]). A copy of Appili’s investor presentation will be available on the Company’s website under the ‘Investor Overview’ page.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

H.C. Wainwright & Co – 22nd Annual Global Investment Conference
Date: Tuesday, September 15
Time: 4:00 PM ET
Access via Webcasting Link: View Source
About the Conference
H.C. Wainwright & Co’s 22nd Annual Global Investment Conference is a virtual event occurring September 14-16, 2020. It includes leading industry keynote speakers and presenting companies, investor one-on-one meetings, networking opportunities with attendees, and an evening of virtual entertainment.

Maxim Group’s Antifungal Webinar
Title: A Too Quiet Pandemic – Fungal Disease
Date: Thursday, September 17
Time: 1:00 PM ET
Access: https://bit.ly/3bDWHJ9
About the Conference
With much of the mainstream focus on antibiotic drug resistance and viral diseases, fungi and their related invasive and mucosal infections still seem to go relatively unnoticed. There are over 1.6 million deaths annually related to severe fungal infections and there are tens of millions of mucosal infections. The need for new anti-infectives could never be greater, especially antifungals where there are only three existing classes of drugs with too few options in each. Fungal-driven diseases are diseases of opportunity, often arising in settings of immune function changes or secondary to other conditions like cancer therapy and transplant, even secondary to viral infections including COVID-19. However, while these are diseases of opportunity for fungi and representative of its own pandemic, with it comes opportunity for novel therapeutics to emerge. The unmet need has ushered in not only innovative approaches, but also changes in regulatory guidelines, incentives for drug developers, changes in trial design and execution, changes in the views of payers and renewed focus of the investment community. This panel discussion includes top innovators in the fungal drug development space.

On September 10, 2020 BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, reported that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences (Press release, BiomX, SEP 10, 2020, View Source [SID1234564974]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: HC Wainwright 22nd Annual Global Investments Conference
Date: Monday, Sept. 14, 2020
Time: 12:30 p.m. EDT
Webcast link: View Source

Event: Cantor 2020 Virtual Global Healthcare Conference
Date: Wednesday, Sept. 16, 2020
Time: 11:20 a.m. EDT
Webcast link: View Source

Webcasts will also be available in the Events section of the BiomX website at www.biomx.com. Archived replays will be accessible following each event.

On September 10, 2020 Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, reported that management will present virtually at the following upcoming investor conferences (Press release, Verastem, SEP 10, 2020, View Source [SID1234564973]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 p.m. Eastern Time
Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 3:20 p.m. Eastern Time
A live webcast of the presentations will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.